IFF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
International Flavors & Fragrances Inc (IFF) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent financial challenges, the stock shows positive insider buying trends, strong analyst support with upward price target revisions, and a SwingMax signal indicating a buy-low opportunity. The stock's potential for recovery, coupled with its strategic portfolio optimization, aligns well with a long-term investment approach.
The MACD histogram is negative (-0.137) but contracting, indicating potential stabilization. RSI is neutral at 57.808, suggesting no overbought or oversold conditions. Moving averages are converging, indicating a lack of strong directional momentum. Key support and resistance levels are at S1: 66.363 and R1: 72.032, with the stock currently trading near resistance.
Insider buying has surged by 109,558.63% over the last month, signaling confidence in the company's future.
Analysts have consistently raised price targets, with Citi, Deutsche Bank, and BofA projecting targets as high as $
SwingMax signal on 2026-03-25 suggests a buy-low opportunity.
Positive sentiment from news, with a 2.8% YTD stock price increase despite market volatility.
Financial performance in Q4 2025 showed significant declines, with revenue down -6.57% YoY, net income down -219.23% YoY, and EPS down -220.00% YoY.
Gross margin dropped to 29.2%, down -3.34% YoY, reflecting operational challenges.
The MACD remains below zero, and the stock is trading near resistance, indicating limited short-term upside.
In Q4 2025, the company faced a challenging quarter with revenue at $2.589 billion (-6.57% YoY), net income at $31 million (-219.23% YoY), and EPS at $0.12 (-220.00% YoY). Gross margin also declined to 29.2% (-3.34% YoY), reflecting weaker profitability.
Analysts are bullish on IFF, with multiple firms raising price targets recently. Citi, Deutsche Bank, and BofA have set targets as high as $100, citing portfolio optimization progress and a strategic shift towards organic growth. Oppenheimer upgraded the stock to Outperform, emphasizing favorable market forces and renewed sentiment in chemicals and consumer staples.
